"In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

SOURCE CITATION Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150-60. 34449183. Click to show full abstract

SOURCE CITATION Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150-60. 34449183.

Keywords: tavr edoxaban; vkas composite; edoxaban noninferior; composite adverse; adverse events; noninferior vkas

Journal Title: Annals of Internal Medicine
Year Published: 2022

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
2

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended